.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AJ05_Avacopan.Avacopan .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AJ05_Avacopan.Avacopan| name: | Avacopan | |
| ATC code: | L04AJ05 | route: | oral |
| compartments: | 2 | |
| dosage: | 30 | mg |
| volume of distribution: | 345 | L |
| clearance: | 14.6 | L/h |
| other parameters in model implementation | ||
Avacopan is an orally administered selective C5a receptor antagonist used for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis, such as granulomatosis with polyangiitis and microscopic polyangiitis. Approved by regulatory authorities including the FDA (under brand name Tavneos) since 2021.
Pharmacokinetic parameters reported in adults, both healthy volunteers and patients with ANCA-associated vasculitis, after oral administration of avacopan at steady state.
Miao, S, et al., & Trivedi, A (2024). Food Effect and Pharmacokinetic Bridging of Avacopan in Caucasian and Japanese Healthy Participants. Clinical pharmacology in drug development 13(9) 1011–1023. DOI:10.1002/cpdd.1436 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38993035